Antares Pharma Inc. announced that its experimental bladder control drug met the main goal of the late-stage trial.  The main goal was to show a statistically significant reduction in urinary incontinence for two different doses.  The company is now seeking approval for the drug ( Anturol ) to treat patients with overactive bladder or urge incontinence.
According to published reports, over 30 million Americans have overactive bladder, a condition whose sufferers have a sudden need to urinate, which can happen at any time whether or not the bladder is full.
Antares said both doses of Anturol showed a low incidence of side effects.